撼动苹果CAR-T(嵌合抗原受体T细胞疗法)——可持续性要求美国创新
本文评述CAR-T细胞免疫疗法的发展与挑战。2017年底美国FDA批准Yescarta(阿基仑赛)和Kymriah(替沙仑赛)两个产品,FDA预计到2025年每年审评批准10至20个此类治疗,但两种已批准疗法的实际采用缓慢。
要点
- 2017年底FDA批准Yescarta(阿基仑赛)和Kymriah(替沙仑赛)两个CAR-T产品。
- FDA待审细胞和基因治疗新药申请近1000项,预计2025年每年批准10至20个。
- 尽管前景巨大且需求迫切,两种FDA已批准疗法的实际采用一直缓慢。
核心结论
- 尽管CAR-T细胞具有巨大前景并满足迫切未满足需求,两种FDA已批准疗法的实际采用一直缓慢。
研究设计与样本
- 本文为评述文章,未报告系统检索方法或样本量。
主要发现
- 首个CAR-T应用靶向淋系恶性肿瘤的CD19抗原,这些「活药物」的特异性、治愈潜力和可推广性使其被《科学》杂志宣布为2019年度突破。
- Yescarta(阿基仑赛)和Kymriah(替沙仑赛)于2017年底获FDA批准,FDA局长Scott Gottlieb称其为「医学创新的新前沿」。
- 近1000项细胞和基因治疗新药申请待FDA审评,FDA预计到2025年每年审评批准10至20个此类治疗。
- 两种FDA已批准疗法的实际采用一直缓慢。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seldom has a medical advance in cancer therapy been as pivotal as the advent of chimeric antigen receptor (CAR)-T-cell immunotherapy. While the first applications targeted the CD19 antigen on lymphoid malignancies, the incredible specificity of these 'living drugs', curative potential and generalisability to other targets have richly justified their declaration as 2019's breakthrough of the year by Science magazine. Two CAR-T products, Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) were Food and Drug Administration (FDA)-approved in the USA in late 2017, with the FDA commissioner Scott Gottlieb heralding 'a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer'. Building upon early enthusiasm, nearly 1000 cell- and gene-therapy investigational new drug applications are pending with the FDA, which expects to review and approve between 10 and 20 such treatments annually by 2025. Despite the enormous promise and urgent unmet need fulfilled by CAR-T cells, the real-world adoption of the two FDA-approved treatments has been slow.
引用
- Pantin J, Battiwalla M. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation. Br J Haematol. 2020. PMID: 32358811. doi:10.1111/bjh.16685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。